Appointments at Inspire, King, Bionor and Oncothyreon – People on the move
Robert Savel has been hired by Inspire Pharmaceuticals as SVP and chief technical officer. Savel will be responsible for all manufacturing and technical operations. Before joining Inspire, Savel worked at PDL Biopharma and Johnson & Johnson.
King Pharmaceuticals has named Jeffrey Bailey as chief commercial officer. Bailey has previously worked at Novartis, Janssen Pharmaceutica and Johnson & Johnson.
Henrik Lund has joined Bionor Pharma as CEO, replacing Trond Syvertsen. Lund joins from AstraZeneca where he was responsible for clinical development activities in Europe, Asia and Latin America.
Oncothyreon has appointed Julie Eastland as chief financial officer and vice president (VP), corporate development. Eastland has previously worked at VLST, Dendreon and Amgen.
Stephen Stamp has been named as an independent non-executive director to the EUSA Pharma board. Stamp has experience of the speciality pharma sector from his time at Xanodyne Pharmaceuticals, Shire Pharmaceuticals and KV Pharmaceuticals.
Novasep has named Bernard Dubois as chairman of its supervisory board, replacing Pietro Stefanutti. Dubois is the former SVP, head of global industrial operations at Aventis and has also worked as CEO of Cooper.
John-Michel Huss has been appointed as president and CEO of Theratechnologies. Huss has more than 20 years of pharma experience working at companies including Merck & Co and Sanofi-Aventis.
The UK BioIndustry Association (BIA) has elected Tim Edwards as chairman. Edwards succeeds Clive Dix who is stepping down after two years in the post. Currently Edwards is CEO of Cellzome and has also worked at British Biotech.
